ACTUATE THERAPEUTICS

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

07 5 2025 08:00:01 提供 Nasdaq GlobeNewswire

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

06 5 2025 08:00:01 提供 Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

30 4 2025 08:00:00 提供 Nasdaq GlobeNewswire

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 4 2025 10:24:10 提供 Nasdaq GlobeNewswire

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

17 4 2025 08:00:00 提供 Nasdaq GlobeNewswire

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

25 2 2025 08:00:00 提供 Nasdaq GlobeNewswire

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

06 2 2025 08:00:00 提供 Nasdaq GlobeNewswire

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

07 1 2025 08:00:01 提供 Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 12 2024 08:28:17 提供 Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Actuate Therapeutics to be Added to Russell 2000® Index

26 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

12 11 2024 08:00:03 提供 Nasdaq GlobeNewswire

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

29 10 2024 18:39:24 提供 Nasdaq GlobeNewswire

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

23 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

16 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

11 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

09 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 9 2024 09:10:56 提供 Nasdaq GlobeNewswire

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024

20 8 2024 09:00:00 提供 Nasdaq GlobeNewswire